Over the recent years, potential associations between Toxoplasma gondii (T. gondii) infection and cancer risk have attracted a lot of attention. Nevertheless, the association between T. gondii infection and oral cancer remains relatively unexplored. We performed a case-control study of 861 oral cancer patients and 861 control subjects from eastern China with the aim to detect antibodies to T. gondii by enzyme-linked immunosorbent assay (ELISA) in these patients. The results showed that oral cancer patients (21.72%, 187/861) had a significantly higher seroprevalence than control subjects (8.25%, 71/861) (P < 0.001). Among them, 144 (16.72%) oral cancer patients and 71 (8.25%) control subjects were positive for IgG antibodies to T. gondii, while 54 (6.27%) oral cancer patients and 9 (1.05%) controls were positive for IgM antibodies to T. gondii. In addition, multiple logistic analysis showed that T. gondii infection in oral cancer patients was associated with blood transfusion history, keeping cats at home, and oyster consumption. To our knowledge, this is the first study that provided a serological evidence of an association between T. gondii infection and oral cancer patients. However, further studies are necessary to elucidate the role of T. gondii in oral cancer patients.
Human cervical cancer is often associated with human papilloma virus (HPV). HPV products, such as the oncoproteins E6 and E7, are known to disrupt the function of TP53 (formerly known as p53). The protein encoded by the TP53 gene plays a central role in managing cellular damage. Interferons are known to down-regulate E6/E7 and may therefore restore TP53 function and influence radiation sensitivity. We investigated whether IFNB or IFNG, at various concentrations (2- 300 IU/ml) and for a range of durations of exposure (from 48 h before to 8 h after irradiation), were able to modify the radiation response of HeLa, C4-1, Me-180, C33-A and SiHa cells. In parallel to the clonogenic assays, we analyzed the effect on the mRNA that encodes IFNB and E6 by Northern blotting in the same experimental conditions. A significant change in the initial slope of the dose-response curve was observed more consistently with IFNB than with IFNG. No changes in the mRNA or protein level of TP53 and E6 could be detected. Thus other mechanisms of action need to be investigated to explain radiosensitization with recombinant IFNB in cells of human cervical cancer cell lines.
BackgroundPsoriasis is a common chronic inflammatory disease of the skin[1]. The IL-23/IL-17 immune pathway plays a vital role in promoting Psoriasis pathogenesis[2]. Tildrakizumab, a humanized IgG1 monoclonal antibody against interleukin 23 p19, is currently used in the treatment of patients with psoriasis.ObjectivesThis study aimed to evaluate the efficacy of tildrakizumab in the treatment of psoriasis.MethodsFive databases, including PubMed, Embase, Medline, Web of Science, and Cochrane Library, were retrieved from their establishment to January 2, 2023. We used the EndNote X9 software to filter the retrieved articles according to the inclusion and exclusion criteria. Heterogeneity was tested using I-squared (I2). When I2>50%, we choosed the random effects model for data analysis, conversely, a fixed effects model. Publication bias was assessed using the Egger test. All analyzes were performed in STATA 12.0.ResultsWe included 6 studies, 2,395 patients in the Tildrakizumab group and 552 patients in the placebo group (Table 1). Results of the meta-analysis showed that 68% of patients with psoriasis met the PAIS75 remission criteria after taking Tildrakizumab [Rate =0.68 95%CI(0.66, 0.70), P<0.001], and they had significantly higher PASI75 response rates than the placebo group [RR=11.390, 95%CI (8.08, 16.06), P<0.001]. Compared to the placebo group, patients in the Tildrakizumab group had a significantly higher remission rate of PASI90 [RR=26.751, 95%CI (15.282,46.827), P<0.001]. In addition, patients taking Tildrakizumab had an average 15-point reduction in PASI scores [Rate=-14.854 95%CI(-19.146, -10.561), P<0.001], and 45% of patients achieved PASI100 remission criteria [Rate= 0.450, 95%CI (0.131, 0.769), P=0.006] (Figure 1).ConclusionThis study showed that Tildrakizumab improved disease activity and increased clinical remission rates in patients with psoriasis, demonstrating a better therapeutic effect.References[1]Griffiths CEM, Armstrong AW, Gudjonsson JE, et al. Psoriasis. Lancet 2021; 397 (10281): 1301-1315. doi: 10.1016/s0140-6736(20)32549-6.[2]Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol 2018; 55 (3): 379-390. doi: 10.1007/s12016-018-8702-3.Table 1.Population characteristics included in the studyAuthor(Year)Population (include in analysis)Age (Mean±SD)Gender (male %)TILPBOTILPBOTILPBOKristian Reich(2017)617(617)155(154)46.65±13.1447.9±13.570.264.5K. Papp(2015)309(102)46(41)44.79±13.0445.9±11.775.182.5Alessandra Narcisi.(2022)237(121)NA48.6±14.6NA59.9NAY Poulin(2020)1413(1413)357(357)NA72.170.0Cantrell, W.(2021)248(135)NANANAT Graier(2022)15(7)NA45.9±14.1NA73.3NAAcknowledgements:NIL.Disclosure of InterestsNone Declared.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.